ALLMedicine™ Dysfibrinogenemia Center
Research & Reviews 62 results
http://emedicine.medscape.com/article/2086278-overview
May 5th, 2022 - Reference Range Thrombin time is a screening coagulation test designed to assess fibrin formation from fibrinogen in plasma. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds), but this depends on the tes...
https://emedicine.medscape.com/article/199723-overview
Apr 28th, 2022 - Practice Essentials Dysfibrinogenemia is a rare coagulation disorder resulting from an abnormal or decreaased level of fibrinogen, which is a 340 kDa glycoprotein produced in the liver, necessary to form blood clots and control bleeding. Dysfibrin...
https://doi.org/10.1055/s-0041-1742170
Seminars in Thrombosis and Hemostasis; Richard M, Celeny D et. al.
Jan 25th, 2022 - Fibrinogen is a complex protein that plays a key role in the blood clotting process. It is a hexamer composed of two copies of three distinct chains: Aα, Bβ, and γ encoded by three genes, FGA, FGB, and FGG, clustered on the long arm of chromosome ...
https://doi.org/10.1007/s10840-021-01073-0 10.1378/chest.09-1584 10.1097/FJC.0000000000000607 10.1111/hae.12445 10.1007/s11239-020-02097-5 10.1111/hae.12055 10.1016/j.hrcr.2019.01.014 10.1111/ejh.13296 10.1053/spen.2000.20075 10.1111/jth.12916 10.1111/j.1538-7836.2005.01204.x 10.1111/j.1538-7836.2009.03678.x 10.1056/NEJMcp1810479 10.1016/j.leukres.2005.03.004 10.1055/s-0039-1698756
Journal of Interventional Cardiac Electrophysiology : an ... Dognin N, Salaun E et. al.
Nov 26th, 2021 - We report our single-center experience with percutaneous left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF) and primary hemostasis disorders (HD). Consecutive patients with primary HD who underwent a perc...
https://doi.org/10.1016/j.hoc.2021.07.002
Hematology/oncology Clinics of North America; Cheves TA, DeMarinis S et. al.
Aug 16th, 2021 - In patients presenting with a suspect hereditary bleeding disorder a detailed bleeding history is first obtained. Testing proceeds in a tiered manner with platelet count, platelet morphology, platelet histogram, PFA-100, fibrinogen, prothrombin ti...
Drugs 2 results
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc
Jun 15th, 2021 - RIASTAP®, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogen...
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a93f4-d84b-1fa9-51ed-32f6140bf423
Dec 22nd, 2020 - FIBRYGA is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. FIBRYGA is not indicated for dysfibrin...
News 1 results
https://reference.medscape.com/viewarticle/902400_2
Dec 3rd, 2018 - Nephrotic syndrome is one of several disease states that increase a patient's risk of developing VTE. VTE associated with nephrotic syndrome appears to be due to a hypercoagulable state resulting from urinary loss of anticoagulant proteins, togeth...
